BMRN Annual Accounts Payable
$315.51 M
+$84.27 M+36.44%
31 December 2023
Summary:
As of January 22, 2025, BMRN annual accounts payable is $315.51 million, with the most recent change of +$84.27 million (+36.44%) on December 31, 2023. During the last 3 years, it has risen by +$124.08 million (+64.82%). BMRN annual accounts payable is now at all-time high.BMRN Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Quarterly Accounts Payable
$312.32 M
+$54.91 M+21.33%
30 September 2024
Summary:
As of January 22, 2025, BMRN quarterly accounts payable is $312.32 million, with the most recent change of +$54.91 million (+21.33%) on September 30, 2024. Over the past year, it has dropped by -$3.19 million (-1.01%). BMRN quarterly accounts payable is now -1.01% below its all-time high of $315.51 million, reached on December 31, 2023.BMRN Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +36.4% | -1.0% |
| 3 y3 years | +64.8% | +18.0% |
| 5 y5 years | +52.0% | +18.0% |
BMRN Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +58.0% | -1.0% | +66.3% |
| 5 y | 5-year | at high | +64.8% | -1.0% | +89.3% |
| alltime | all time | at high | >+9999.0% | -1.0% | >+9999.0% |
BioMarin Pharmaceutical Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $312.32 M(+21.3%) |
| June 2024 | - | $257.41 M(-11.9%) |
| Mar 2024 | - | $292.24 M(-7.4%) |
| Dec 2023 | $315.51 M(+36.4%) | $315.51 M(+4.7%) |
| Sept 2023 | - | $301.37 M(+8.4%) |
| June 2023 | - | $277.94 M(+5.0%) |
| Mar 2023 | - | $264.78 M(+14.5%) |
| Dec 2022 | $231.24 M(+15.8%) | $231.24 M(+11.6%) |
| Sept 2022 | - | $207.16 M(+4.0%) |
| June 2022 | - | $199.25 M(+6.1%) |
| Mar 2022 | - | $187.81 M(-5.9%) |
| Dec 2021 | $199.68 M(+4.3%) | $199.68 M(-1.8%) |
| Sept 2021 | - | $203.32 M(+15.5%) |
| June 2021 | - | $176.07 M(+6.7%) |
| Mar 2021 | - | $165.00 M(-13.8%) |
| Dec 2020 | $191.43 M(-20.6%) | $191.43 M(-12.2%) |
| Sept 2020 | - | $218.02 M(+5.9%) |
| June 2020 | - | $205.87 M(-12.5%) |
| Mar 2020 | - | $235.16 M(-2.4%) |
| Dec 2019 | $240.98 M(+16.1%) | $240.98 M(+6.3%) |
| Sept 2019 | - | $226.77 M(+1.3%) |
| June 2019 | - | $223.95 M(-0.2%) |
| Mar 2019 | - | $224.38 M(+8.1%) |
| Dec 2018 | $207.62 M(+24.6%) | $207.62 M(+17.0%) |
| Sept 2018 | - | $177.40 M(+6.6%) |
| June 2018 | - | $166.42 M(-3.4%) |
| Mar 2018 | - | $172.19 M(+3.3%) |
| Dec 2017 | $166.62 M(-12.9%) | $166.62 M(+6.1%) |
| Sept 2017 | - | $157.02 M(-0.8%) |
| June 2017 | - | $158.23 M(+16.7%) |
| Mar 2017 | - | $135.60 M(-29.1%) |
| Dec 2016 | $191.35 M(+6.7%) | $191.35 M(+28.6%) |
| Sept 2016 | - | $148.77 M(-3.2%) |
| June 2016 | - | $153.65 M(+0.5%) |
| Mar 2016 | - | $152.86 M(-14.7%) |
| Dec 2015 | $179.29 M(+28.5%) | $179.29 M(+10.0%) |
| Sept 2015 | - | $162.93 M(+20.0%) |
| June 2015 | - | $135.77 M(+4.4%) |
| Mar 2015 | - | $130.07 M(-6.8%) |
| Dec 2014 | $139.51 M(+46.4%) | $139.51 M(+20.5%) |
| Sept 2014 | - | $115.75 M(+14.5%) |
| June 2014 | - | $101.05 M(+26.8%) |
| Mar 2014 | - | $79.72 M(-16.3%) |
| Dec 2013 | $95.30 M(+41.9%) | $95.30 M(+28.3%) |
| Sept 2013 | - | $74.30 M(+8.7%) |
| June 2013 | - | $68.36 M(-2.1%) |
| Mar 2013 | - | $69.81 M(+4.0%) |
| Dec 2012 | $67.15 M(+86.1%) | $67.15 M(+486.0%) |
| Sept 2012 | - | $11.46 M(-8.3%) |
| June 2012 | - | $12.50 M(+0.5%) |
| Mar 2012 | - | $12.44 M(-65.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2011 | $36.09 M(+628.2%) | $36.09 M(+407.8%) |
| Sept 2011 | - | $7.11 M(-2.0%) |
| June 2011 | - | $7.25 M(+37.5%) |
| Mar 2011 | - | $5.27 M(+6.4%) |
| Dec 2010 | $4.96 M(-34.5%) | $4.96 M(-31.0%) |
| Sept 2010 | - | $7.18 M(-26.0%) |
| June 2010 | - | $9.71 M(+196.3%) |
| Mar 2010 | - | $3.28 M(-56.7%) |
| Dec 2009 | $7.57 M(+547.3%) | $7.57 M(+264.5%) |
| Sept 2009 | - | $2.08 M(-93.3%) |
| June 2009 | - | $31.01 M(+498.9%) |
| Mar 2009 | - | $5.18 M(+155.2%) |
| Sept 2008 | - | $2.03 M(-28.7%) |
| June 2008 | - | $2.85 M(+22.4%) |
| Mar 2008 | - | $2.33 M(+99.0%) |
| Dec 2007 | $1.17 M(-48.8%) | $1.17 M(-11.0%) |
| Sept 2007 | - | $1.31 M(+74.1%) |
| June 2007 | - | $754.00 K(+0.8%) |
| Mar 2007 | - | $748.00 K(-67.3%) |
| Dec 2006 | $2.29 M(+372.1%) | $2.29 M(+52.5%) |
| Sept 2006 | - | $1.50 M(+548.5%) |
| June 2006 | - | $231.00 K(-47.5%) |
| Mar 2006 | - | $440.00 K(-9.1%) |
| Dec 2005 | $484.00 K(-98.2%) | $484.00 K(-10.2%) |
| Sept 2005 | - | $539.00 K(-76.8%) |
| June 2005 | - | $2.32 M(-5.9%) |
| Mar 2005 | - | $2.47 M(-90.9%) |
| Dec 2004 | $27.25 M(+169.8%) | $27.25 M(+5747.4%) |
| Sept 2004 | - | $466.00 K(-44.5%) |
| June 2004 | - | $840.00 K(-63.5%) |
| Mar 2004 | - | $2.30 M(-77.2%) |
| Dec 2003 | $10.10 M(+156.9%) | $10.10 M(-24.6%) |
| Sept 2003 | - | $13.40 M(+10.5%) |
| June 2003 | - | $12.12 M(+27.2%) |
| Mar 2003 | - | $9.53 M(+142.5%) |
| Dec 2002 | $3.93 M(-8.3%) | $3.93 M(+415.1%) |
| Sept 2002 | - | $763.00 K(-62.1%) |
| June 2002 | - | $2.01 M(-36.8%) |
| Mar 2002 | - | $3.19 M(-25.6%) |
| Dec 2001 | $4.28 M(-9.8%) | $4.28 M(+9.2%) |
| Sept 2001 | - | $3.92 M(+28.7%) |
| June 2001 | - | $3.05 M(+88.7%) |
| Mar 2001 | - | $1.62 M(-66.0%) |
| Dec 2000 | $4.75 M(+53.4%) | $4.75 M(+164.9%) |
| Sept 2000 | - | $1.79 M(+81.0%) |
| June 2000 | - | $990.00 K(-27.6%) |
| Mar 2000 | - | $1.37 M(-55.8%) |
| Dec 1999 | $3.10 M(+121.1%) | $3.10 M(-38.1%) |
| Sept 1999 | - | $5.00 M(-16.7%) |
| June 1999 | - | $6.00 M(+650.0%) |
| Mar 1999 | - | $800.00 K |
| Dec 1998 | $1.40 M | - |
FAQ
- What is BioMarin Pharmaceutical annual accounts payable?
- What is the all time high annual accounts payable for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual accounts payable year-on-year change?
- What is BioMarin Pharmaceutical quarterly accounts payable?
- What is the all time high quarterly accounts payable for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly accounts payable year-on-year change?
What is BioMarin Pharmaceutical annual accounts payable?
The current annual accounts payable of BMRN is $315.51 M
What is the all time high annual accounts payable for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual accounts payable is $315.51 M
What is BioMarin Pharmaceutical annual accounts payable year-on-year change?
Over the past year, BMRN annual accounts payable has changed by +$84.27 M (+36.44%)
What is BioMarin Pharmaceutical quarterly accounts payable?
The current quarterly accounts payable of BMRN is $312.32 M
What is the all time high quarterly accounts payable for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly accounts payable is $315.51 M
What is BioMarin Pharmaceutical quarterly accounts payable year-on-year change?
Over the past year, BMRN quarterly accounts payable has changed by -$3.19 M (-1.01%)